Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

James Foster, CEO and co-founder of Virax Biolabs, discusses how companies can strategize despite hard-to-predict regulatory headwinds.

Artificial intelligence (AI) and machine learning have transformed this landscape by enabling complex, predictive alerts ...

As part of the funding, Latent Labs aims to leverage generative artificial intelligence to computationally create novel ...

Robert F. Kennedy Jr. will serve as Secretary of Health and Human Services. 1 The US Senate voted 52-48 in favor of Kennedy ...

Evrysdi is a non-invasive, disease-modifying option that can be swallowed whole or dispersed in water for patients with ...

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

In this part of his Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, identifies strategies ...

Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be ...

In a recent article titled “ Big Pharma says ‘Thanks, but No Thanks’ to their own HEOR groups, ” Professor Scott Ramsey from ...